Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronickKidney disease stages 3 and 4 (2019)
- Authors:
- Autor USP: GIANNELLA, MARIA LUCIA CARDILLO CORREA - FM
- Unidade: FM
- DOI: 10.1016/j.clinthera.2019.07.011
- Subjects: INSULINA; GLICEMIA; HIPOGLICEMIA; DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; INSUFICIÊNCIA RENAL CRÔNICA
- Language: Inglês
- Imprenta:
- Publisher place: Bridgewater
- Date published: 2019
- Source:
- Título do periódico: Clinical therapeutics
- ISSN: 0149-2918
- Volume/Número/Paginação/Ano: v. 41, n. 10, p. 2008-2020, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
BETONICO, Carolina C et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronickKidney disease stages 3 and 4. Clinical therapeutics, v. 41, n. 10, p. 2008-2020, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.07.011. Acesso em: 30 abr. 2024. -
APA
Betonico, C. C., Titan, S. M. O., Lira, A., Pelaes, T. S., Giannella, M. L. C. C., Nery, M., & Queiroz, M. (2019). Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronickKidney disease stages 3 and 4. Clinical therapeutics, 41( 10), 2008-2020. doi:10.1016/j.clinthera.2019.07.011 -
NLM
Betonico CC, Titan SMO, Lira A, Pelaes TS, Giannella MLCC, Nery M, Queiroz M. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronickKidney disease stages 3 and 4 [Internet]. Clinical therapeutics. 2019 ; 41( 10): 2008-2020.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1016/j.clinthera.2019.07.011 -
Vancouver
Betonico CC, Titan SMO, Lira A, Pelaes TS, Giannella MLCC, Nery M, Queiroz M. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronickKidney disease stages 3 and 4 [Internet]. Clinical therapeutics. 2019 ; 41( 10): 2008-2020.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1016/j.clinthera.2019.07.011 - Efeito dos produtos finais de glicacao avancada (AGES) sobre a expressao dos genes do fator de crescimento insulina simile do tipo 1 (IgF-1) e de sua proteina de ligacao do tipo 4 (IgFBP-4) em celulas musculares lisas isoladas de aorta humana em cultura
- Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients
- Pioglitazone modulates the lipid metabolism, cell cycle, and cell death gene expression profile in pancreatic islets
- Evalution of the expression of incretin receptors in rat pancreatic islets explosed to human amylin and to lipotoxicity
- Visceral adiposity syndrome
- Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes
- Bases moleculares da oncogênese hipofisária
- MicroRNAs 1915-3p, 2861, and 4532 Are Associated with Long-Term Renal Function Decline in Type 1 Diabetes [Carta]
- Reproducibility of a nylon fishing line as a screening test for diabetic foot ulceration risk [Editorial]
- Bases da biologia molecular
Informações sobre o DOI: 10.1016/j.clinthera.2019.07.011 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
